×
News Home

Is Neurocrine Biosciences, Inc. (NBIX) a Winner in the Healthcare Sector?

Friday, November 19, 2021 02:04 PM | InvestorsObserver Analysts
Is Neurocrine Biosciences, Inc. (NBIX) a Winner in the Healthcare Sector?

Neurocrine Biosciences, Inc. (NBIX) is near the top in its sector according to InvestorsObserver. NBIX gets an overall rating of 40. That means it scores higher than 40% of stocks. Neurocrine Biosciences, Inc. gets a 72 rank in the Healthcare sector. Healthcare is number 7 out of 11 sectors.

Overall Score - 40
NBIX has an Overall Score of 40. Find out what this means to you and get the rest of the rankings on NBIX!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. *Investors Observer* makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in healthcare or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Neurocrine Biosciences, Inc. Stock Today?

Neurocrine Biosciences, Inc. (NBIX) stock is trading at $85.93 as of 1:49 PM on Friday, Nov 19, a loss of -$1.58, or -1.81% from the previous closing price of $87.51. The stock has traded between $85.70 and $87.66 so far today. Volume today is light. So far 347,721 shares have traded compared to average volume of 743,462 shares. Click Here to get the full Stock Report for Neurocrine Biosciences, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App